Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 3/2003

01-03-2003 | Original Article

A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer

Authors: Yukio Iwashita, Kouichirou Tahara, Shigeru Goto, Atsushi Sasaki, Seiichiro Kai, Masataka Seike, Chao-Long Chen, Katsunori Kawano, Seigo Kitano

Published in: Cancer Immunology, Immunotherapy | Issue 3/2003

Login to get access

Abstract

Background/aims

To evaluate the safety and feasibility of immunotherapy based on autologous dendritic cells (DC) for patients with unresectable primary liver cancer (PLC).

Methods

A total of ten patients were enrolled and immunized with DCs. Autologous DCs were generated ex vivo in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). Cells were then pulsed with tumor lysate (TL), tumor necrosis factor-α (TNF-α) and keyhole limpet hemocyanin (KLH). Non-adherent cells were collected on day 9 and cells were administered into the inguinal lymph node. Each patient received 1–10×106 cells four times at weekly intervals.

Results

Immunization was well tolerated in all patients without significant toxicity. DC vaccination induced delayed-type hypersensitivity (DTH) against KLH in seven out of ten patients. In one patient, one of the two liver tumors (tumor in segment 7, 13 mm in diameter) decreased in size to 7 mm and showed necrotic change on computed tomography examination after eight immunizations. In two patients, serum levels of tumor markers decreased after vaccination.

Conclusion

The present clinical trial suggested that immunization by TL-pulsed DCs is feasible in patients with unresectable PLC without any toxicity. Further improvement in the clinical results of immunotherapy might be expected by modifying the therapeutic protocol.
Literature
1.
Ahrendt SA, Nakeeb A, Pitt HA (2001) Cholangiocarcinoma. Clin Liver Dis 5:191PubMed
2.
Auffermann-Gretzinger S, Keeffe EB, Levy S (2001) Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97:3171CrossRefPubMed
3.
Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR (1997) Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 186:65PubMed
4.
Brossart P, Bevan MJ (1997) Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 90:1594PubMed
5.
Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH, Economou JS (1999) Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 59:3134PubMed
6.
Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH, Economou JS (2001) T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 166:5300PubMed
7.
De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T (1996) The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A 93:7149CrossRefPubMed
8.
Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A, Mule J (2000) Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 356:1163CrossRefPubMed
9.
Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ (2001) Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61:8513PubMed
10.
Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy MS (1994) Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263:518PubMed
11.
Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M (1999) Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161:777PubMed
12.
Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52PubMed
13.
Kakumu S, Ito S, Ishikawa T, Mita Y, Tagaya T, Fukuzawa Y, Yoshioka K (2000) Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol 15:431CrossRefPubMed
14.
Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6:332PubMed
15.
Levin B, Amos C (1995) Therapy of unresectable hepatocellular carcinoma (editorial; comment) (published erratum appears in N Engl J Med 1995;333(10):675]. N Engl J Med 332:1294CrossRefPubMed
16.
17.
Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM (2000) Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 191:795PubMed
18.
Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK, Morse MA (1999) Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer 82:121PubMed
19.
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328PubMed
20.
Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, Murai M (2001) Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 7:23PubMed
21.
Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M (2001) Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7:2277PubMed
22.
Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, Murphy GP (1998) Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 35:144CrossRefPubMed
23.
Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109PubMed
24.
Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, Eigler A (2001) Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 61:6445PubMed
25.
Schuster MJ, Wu GY (1997) Gene therapy for hepatocellular carcinoma: progress but many stones yet unturned! (editorial; comment). Gastroenterology 112:656PubMed
26.
Shen Z, Reznikoff G, Dranoff G, Rock KL (1997) Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158:2723PubMed
27.
Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160PubMed
28.
Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271PubMed
29.
Tahara K, Mori M, Sadanaga N, Sakamoto Y, Kitano S, Makuuchi M (1999) Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer 85:1234CrossRefPubMed
30.
Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802CrossRefPubMed
31.
32.
Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA (1995) Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A 92:11993PubMed
33.
Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS (1999) Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 59:3064PubMed
34.
Zhao X, Wei YQ, Peng ZL (2001) Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol Invest 30:33CrossRefPubMed
Metadata
Title
A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer
Authors
Yukio Iwashita
Kouichirou Tahara
Shigeru Goto
Atsushi Sasaki
Seiichiro Kai
Masataka Seike
Chao-Long Chen
Katsunori Kawano
Seigo Kitano
Publication date
01-03-2003
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2003
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-002-0360-9

Other articles of this Issue 3/2003

Cancer Immunology, Immunotherapy 3/2003 Go to the issue

Original Article

Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2

Original Article

Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside

Original Article

Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties

Original Article

Melphalan-induced up-regulation of B7–1 surface expression on normal splenic B cells

Review

IL-12: a promising adjuvant for cancer vaccination

Original Article

Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits